Spyre Therapeutics (United States)

Homepage: spyre.com

Alternate names: Spyre Therapeutics, Spyre Therapeutics, Inc.

ROR: 031dpde20

OpenAlex ID: I4405271776

Stability of Protein Pharmaceuticals: Recent Advances

2024 · Mark Cornell Manning, Ryan E. Holcomb, et al. · Pharmaceutical Research · 45

P911 Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD

2024 · E Zhu, D Rios, et al. · Journal of Crohn s and Colitis · 3

Abs0150 Anti-tl1a Antibody Reduces Disease Symptoms and Pathological Changes in Rat Collagen-induced Arthritis

2025 · M. Siegel, E. Lewis, et al. · Annals of the Rheumatic Diseases · 2

P0789 Combined inhibition of TL1A and integrin β7 is superior to either monotherapy in mouse models of colitis and coadministration of SPY001 and SPY002 demonstrates no drug-drug effects on exposure in non-human primates

2025 · M Siegel, J Friedman, et al. · Journal of Crohn s and Colitis · 2

P0023 Anti-TL1A and anti-IL-23 combination therapy is superior to its constituent monotherapies in mouse anti-CD40 colitis

2026 · M Siegel, D Giles, et al. · Journal of Crohn s and Colitis · 1

P0978 SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations

2026 · S Danese, V Jairath, et al. · Journal of Crohn s and Colitis · 1

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety

2026 · Matthew Siegel, Eric Zhu, et al. · mAbs

P0834 Interim Phase 1 Results for SPY003, a Novel Half-life Extended Monoclonal Antibody Targeting IL-23, Suggest a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease

2026 · Y Vugmeyster, R McLean, et al. · Journal of Crohn s and Colitis

P765 A Novel Monoclonal Antibody Drug Candidate SPY001 Targeting Integrin ɑ4β7 for the Treatment of IBD Demonstrates Prolonged Half-Life in Non-Human Primates

2024 · E Zhu, D Rios, et al. · Journal of Crohn s and Colitis

P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBD

2024 · E Zhu, D Rios, et al. · Journal of Crohn s and Colitis

Works count: 10

Citation count: 95